Literature DB >> 12626850

Cardiovascular effects of donepezil in patients with dementia.

A T McLaren1, J Allen, A Murray, C G Ballard, R A Kenny.   

Abstract

Heart rate variability is used to assess cardiovascular autonomic function. The cholinesterase inhibitor donepezil potentially affects parasympathetic activity. Twenty participants with Alzheimer's disease or dementia with Lewy bodies were treated with donepezil in a pilot study. Power spectral analysis was used to analyse 5 min of beat-to-beat RR interval data in 15 cases. Heart rate variability was significantly reduced following treatment with donepezil; mainly for high frequency (median changed from 581 to 78 ms2; p = 0.001) but also for total power (median changed from 1,563 to 844 ms2; p = 0.047). Donepezil may adversely influence cardiovascular autonomic control. These results indicate the need for larger controlled trials to further investigate the cardiovascular effects of donepezil. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12626850     DOI: 10.1159/000068781

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  13 in total

Review 1.  Pharmacologic modulation of parasympathetic activity in heart failure.

Authors:  Monali Y Desai; Mari A Watanabe; Abhay A Laddu; Paul J Hauptman
Journal:  Heart Fail Rev       Date:  2011-03       Impact factor: 4.214

Review 2.  Short review: Acetylcholinesterase-inhibitors in Alzheimer's disease have opposing effects on blood pressure and cerebral perfusion.

Authors:  J A H R Claassen; A H E A van Beek; M G M Olde Rikkert
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075

3.  Use of clarithromycin and adverse cardiovascular events among older patients receiving donepezil: a population-based, nested case-control study.

Authors:  Janine R Hutson; Hadas D Fischer; Xuesong Wang; Andrea Gruneir; Nick Daneman; Sudeep S Gill; Paula A Rochon; Geoffrey M Anderson
Journal:  Drugs Aging       Date:  2012-03-01       Impact factor: 3.923

4.  Complete atrioventricular block and ventricular tachyarrhythmia associated with donepezil.

Authors:  T Suleyman; P Tevfik; G Abdulkadir; S Ozlem
Journal:  Emerg Med J       Date:  2006-08       Impact factor: 2.740

5.  Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer's disease.

Authors:  Philippe Bordier; Stephane Garrigue; Stephane Lanusse; Julien Margaine; Frederic Robert; Laurent Gencel; Alexia Lafitte
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 6.  Treatment of dementia with Lewy bodies and Parkinson's disease dementia.

Authors:  Clive Ballard; Zunera Kahn; Anne Corbett
Journal:  Drugs Aging       Date:  2011-10-01       Impact factor: 3.923

7.  The effect of donepezil treatment on cardiovascular mortality.

Authors:  K Sato; R Urbano; C Yu; F Yamasaki; T Sato; J Jordan; D Robertson; A Diedrich
Journal:  Clin Pharmacol Ther       Date:  2010-07-21       Impact factor: 6.875

8.  Causes of syncope in patients with Alzheimer's disease treated with donepezil.

Authors:  Philippe Bordier; Stephane Lanusse; Stephane Garrigue; Charlotte Reynard; Frederic Robert; Laurent Gencel; Alexia Lafitte
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 9.  Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.

Authors:  Michal Rolinski; Chris Fox; Ian Maidment; Rupert McShane
Journal:  Cochrane Database Syst Rev       Date:  2012-03-14

10.  Autonomic dysfunction in dementia.

Authors:  L M Allan; C G Ballard; J Allen; A Murray; A W Davidson; I G McKeith; R A Kenny
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12-18       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.